Clinical Trials Logo

Obesity, Morbid clinical trials

View clinical trials related to Obesity, Morbid.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04643301 Withdrawn - Obesity Clinical Trials

Liraglutide for Low-responders After Bariatric Surgery

LIBAR
Start date: December 21, 2020
Phase: N/A
Study type: Interventional

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

NCT ID: NCT04331717 Withdrawn - Obesity, Morbid Clinical Trials

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

BASH-PC
Start date: November 16, 2020
Phase: Phase 2
Study type: Interventional

The standard of care for obese men starting Androgen deprivation therapy (ADT) is physician based dietary and exercise counseling. Interventions to lessen the harmful effects of ADT are needed yet have been limited. Exercise is one strategy that has been attempted however there is conflicting data as to whether or not exercise effectively improves body mass, results in sustained weight loss, improvements in metabolic risk profiles including glucose tolerance and lipid profiles in men starting ADT, or has any effect of progression of cancer. Dietary interventions have been attempted without clear improvement in weight, metabolic factors, quality of life or cancer progression. Bariatric arterial embolization (BAE), given it results in weight loss in obese men and women without cancer, may be able to stave off the harmful side effects of ADT by inducing weight loss. Therefore, the investigators hypothesize that Bariatric Arterial embolization (BAE), done prior to initiation of ADT, will mitigate the weight gain and metabolic side effects associated with ADT, by inducing weight loss of at least 5% in obese men with biochemical recurrent prostate cancer starting ADT. The primary objective is to determine if BAE, done prior to ADT initiation in obese men (with obesity related comorbid condition) with biochemically recurrent prostate cancer, can induce 5% or greater weight loss at 6 months.

NCT ID: NCT04243564 Withdrawn - Morbid Obesity Clinical Trials

Laryngeal Mask in Morbid Obesity

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

Investigators study the performance of both masks, Proseal Laryngeal Mask Airway (PLMA) and I-gel, as temporary ventilatory supraglottic airway devices (SGDs) before tracheal intubation in morbidly obese patients. Data are lacking in such population of patients

NCT ID: NCT04207424 Withdrawn - Morbid Obesity Clinical Trials

Embolization of Arterial Gastric Supply in Obesity

Embargo
Start date: April 2021
Phase: N/A
Study type: Interventional

This study aims to assess safety and efficacy of bariatric embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles, for patients with morbid obesity.

NCT ID: NCT04170335 Withdrawn - Breast Cancer Clinical Trials

Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients

Start date: February 22, 2021
Phase:
Study type: Observational

Breast cancer is the most common cancer in women in the US, and obese women have a 20% to 40% increase in the risk of developing breast cancer compared with normal-weight women. Bariatric surgery is now considered the first line option for weight loss management in morbidly obese patients with failure of medical treatment. There is strong evidence that in early stages of cancer the breast undergoes inflammatory and subsequently density changes that are observable in mammography. The aforementioned alterations have been suggested to be magnified by obesity, potentially due to its pro-inflammatory state. The investigators hypothesized that rapid weight loss following bariatric surgery and henceforth the reduction of inflammatory stress in the breast tissue could potentially have a positive effect in improving breast density and consequently, reducing the risk of breast cancer. In this order of ideas, with this study, the investigators aim to evaluate how breast density is modified after bariatric surgery, and how it impacts the risk of developing breast cancer using The Breast Cancer Surveillance Consortium (BCSC) risk score and calculator in our population.

NCT ID: NCT03538236 Withdrawn - Obesity Clinical Trials

Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess efficacy of intragastric balloon for weight loss in obese patients who also concurrently have NASH.

NCT ID: NCT03530410 Withdrawn - Obesity Clinical Trials

Gastric and Autonomic Functions in Patients With Intragastric Balloon

Start date: March 2021
Phase:
Study type: Observational

The study aims to measure the effect of intragastric balloon on gastric function, particularly gastric accommodation and pace making, and the possible underlying changes in autonomic function

NCT ID: NCT03159130 Withdrawn - Morbid Obesity Clinical Trials

OnQ Pain Pump Effectiveness in Post Operative Pain Control in Bariatric Patients

Start date: June 2012
Phase: N/A
Study type: Observational

This study will assess the efficacy of OnQ pain catheters in pain reduction in the bariatric surgical population and seeks to identify if a quantifiable improved post-operative course occurs in patients receiving a catheter filled with local anesthetic versus that achieved by patients who receive a catheter filled with injectable saline.

NCT ID: NCT03009877 Withdrawn - Obesity, Morbid Clinical Trials

Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

Start date: July 2018
Phase: N/A
Study type: Interventional

Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.

NCT ID: NCT02476474 Withdrawn - Morbid Obesity Clinical Trials

GERD Following Laparoscopic Sleeve Gastrectomy

Start date: July 2023
Phase: N/A
Study type: Interventional

Laparoscopic Sleeve Gastrectomy (LSG) creates a vertical gastrectomy which results in a narrow and tubular shape of stomach. The line of resection starts at 3-6 cm. from pylorus (antrum) toward to the angle of His. The gastric antrum plays a major role in gastric emptying, particularly for solids. Hence, depending upon the starting point of gastric sleeve resection in each center, this can result in difference of the remaining gastric antrum which may affect gastric emptying time after this procedure.